Downstream Hatch-Waxman: Unforeseen IP Ramifications
Law360, New York (July 19, 2005, 12:00 AM EDT) -- Litigation challenging patents on branded drugs has increased exponentially since the passage of the Drug Price Competition and Patent Term Restoration Act of 1984 (commonly referred to as the "Hatch Waxman Act"). As a result of the Act, branded drug manufacturers have faced challenges from generic drug companies to their pharmaceutical patents. This is not surprising. The drafters of the Hatch Waxman Act intended and fully anticipated that patent litigation would be a direct result of the Act. The purpose of the Act was to expedite...
To view the full article, register now.
Try Law360 FREE for seven days
Already a subscriber? Click here to login
